CN1027179C - 利用啤酒酵母基因bari分泌异种蛋白的方法 - Google Patents

利用啤酒酵母基因bari分泌异种蛋白的方法 Download PDF

Info

Publication number
CN1027179C
CN1027179C CN86107554A CN86107554A CN1027179C CN 1027179 C CN1027179 C CN 1027179C CN 86107554 A CN86107554 A CN 86107554A CN 86107554 A CN86107554 A CN 86107554A CN 1027179 C CN1027179 C CN 1027179C
Authority
CN
China
Prior art keywords
bar1
plasmid
fragment
gene
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN86107554A
Other languages
English (en)
Chinese (zh)
Other versions
CN86107554A (zh
Inventor
维维安·L·麦凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of CN86107554A publication Critical patent/CN86107554A/zh
Application granted granted Critical
Publication of CN1027179C publication Critical patent/CN1027179C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN86107554A 1985-10-25 1986-10-25 利用啤酒酵母基因bari分泌异种蛋白的方法 Expired - Lifetime CN1027179C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79130585A 1985-10-25 1985-10-25
US791,305 1985-10-25
PCT/US1986/002198 WO1987002670A1 (en) 1985-10-25 1986-10-20 Method of using bar1 for secreting foreign proteins
USPCT/US86/02198 1986-10-20

Publications (2)

Publication Number Publication Date
CN86107554A CN86107554A (zh) 1987-08-26
CN1027179C true CN1027179C (zh) 1994-12-28

Family

ID=25153298

Family Applications (1)

Application Number Title Priority Date Filing Date
CN86107554A Expired - Lifetime CN1027179C (zh) 1985-10-25 1986-10-25 利用啤酒酵母基因bari分泌异种蛋白的方法

Country Status (13)

Country Link
EP (1) EP0243465A1 (da)
JP (1) JP2523562B2 (da)
CN (1) CN1027179C (da)
AU (2) AU6543286A (da)
CA (1) CA1316133C (da)
CZ (1) CZ284251B6 (da)
DK (1) DK320287A (da)
FI (1) FI872801A7 (da)
HU (1) HU206897B (da)
IE (1) IE63822B1 (da)
SK (1) SK279041B6 (da)
UA (1) UA41863C2 (da)
WO (1) WO1987002670A1 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
AU2334088A (en) * 1987-10-02 1989-05-18 Zymogenetics Inc. Bar1 secretion signal
US5206699A (en) * 1988-05-06 1993-04-27 Gersan Establishment Sensing a narrow frequency band of radiation and gemstones
KR100195632B1 (ko) * 1988-07-23 1999-06-15 스티븐 조지 가랜드 펩티드 및 dna 배열
JPH05505308A (ja) * 1990-03-13 1993-08-12 ハワイ・バイオテクノロジー・グループ・インコーポレイテツド アオパンカビ発現システム
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
WO1996029397A1 (en) 1995-03-17 1996-09-26 Novo Nordisk A/S Novel endoglucanases
CZ297338B6 (cs) 1996-03-01 2006-11-15 Novo Nordisk A/S Peptid potlacující chut k jídlu, farmaceutický prostredek jej obsahující a jeho pouzití
SK11672002A3 (sk) 2000-01-10 2002-12-03 Maxygen Holdings Ltd. Polypeptidový konjugát, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
JP2004534523A (ja) 2001-02-27 2004-11-18 マキシゲン・エイピーエス 新規なインターフェロンβ様分子
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
ES2376694T3 (es) 2001-09-27 2012-03-16 Novo Nordisk Health Care Ag Polipã‰ptidos del factor vii de coagulaciã“n humano.
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
BRPI0609079A2 (pt) 2005-04-18 2010-11-16 Novo Nordisk As peptìdeo, composição farmacêutica, método para o tratamento de cáncer, uso de um peptìdeo construto de ácido nucleico, vetor, hospedeiro, e, anticorpo
CN101243190B (zh) 2005-08-16 2015-05-13 诺沃-诺迪斯克有限公司 制备成熟胰岛素多肽的方法
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
US20100159512A1 (en) 2006-03-06 2010-06-24 Kurt Osther Method for the preparation of recombinant human thrombin and fibrinogen
DK2615108T3 (da) 2006-09-08 2017-01-30 Ambrx Inc Modificeret humant plasmapolypeptid eller fc scaffolds og deres anvendelser
US8518668B2 (en) 2006-09-27 2013-08-27 Novo Nordisk A/S Method for making maturated insulin polypeptides in a fungal cell
EP2076533B1 (en) 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
PL2318029T3 (pl) 2008-07-23 2018-03-30 Elanco Us Inc. Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
US20120107267A1 (en) 2009-03-11 2012-05-03 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
US20120282285A1 (en) 2009-07-17 2012-11-08 Rigshospitalet Masp isoforms as inhibitors of complement activation
JP5931738B2 (ja) 2009-12-01 2016-06-08 ノヴォ ノルディスク アー／エス 新規のペプチジルアルファ−ヒドロキシグリシンアルファ−アミド化リアーゼ
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
BR112012015461A2 (pt) 2009-12-21 2017-01-10 Ambrx Inc polipeptídeos de somatotropina boviina modificados e seus usos
AU2011222883B2 (en) 2010-03-05 2016-05-26 Omeros Corporation Chimeric inhibitor molecules of complement activation
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
US9551714B2 (en) 2010-06-25 2017-01-24 Abbott Laboratories Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies
EP3572091B1 (en) 2010-08-17 2023-12-13 Ambrx, Inc. Modified relaxin polypeptides and their uses
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
BR112013014457A8 (pt) 2010-12-09 2017-12-19 Pasteur Institut usos da enzima 6-metilguanina-dna-metiltrasferase (mgmt, ec 2.1.1.63) para aumentar a produção de proteína heteróloga, bem como vetor de expressão, células recombinantes e polipeptídeo de fusão compreendendo sinal de secreção peptídica e proteína snap
ES2648899T3 (es) 2011-12-09 2018-01-08 Institut Pasteur Inmunoensayo de cribado múltiplex
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
ES2676029T3 (es) 2012-02-09 2018-07-16 Var2 Pharmaceuticals Aps Direccionamiento de glicanos de sulfato de condroitina
EP2906693A1 (en) 2012-10-15 2015-08-19 Novo Nordisk Health Care AG Coagulation factor vii polypeptides
JP2014128262A (ja) * 2012-11-27 2014-07-10 Kirin Brewery Co Ltd 接合能を持つ酵母細胞株のスクリーニング方法
AU2019263303A1 (en) 2018-05-01 2020-12-24 Ambrx, Inc. A method for optimizing antibody expression
EP3821244A1 (en) 2018-07-13 2021-05-19 Varct Diagnostics ApS Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa
DK3849614T3 (da) 2018-09-11 2024-02-26 Ambrx Inc Interleukin-2-polypeptidkonjugater og anvendelser deraf
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
AU2020223031B2 (en) 2019-02-12 2024-08-29 Ambrx, Inc. Compositions containing, methods and uses of antibody-TLR agonist conjugates
MX2022011163A (es) 2020-03-11 2022-10-18 Ambrx Inc Conjugados de polipeptidos de interleucina-2 y sus usos.
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
CA3188349A1 (en) 2020-08-04 2022-02-10 A. Scott Muerhoff Improved methods and kits for detecting sars-cov-2 protein in a sample
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
EP4271998A1 (en) 2020-12-30 2023-11-08 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
EP4313163A1 (en) 2021-04-03 2024-02-07 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
CN115806889B (zh) * 2022-09-28 2024-06-11 山东大学 一种提高基因表达水平的酿酒酵母工程菌及其构建方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4613572A (en) * 1983-08-15 1986-09-23 Kansas State University Research Foundation Yeast BAR1 gene plasmid
JPS61247384A (ja) * 1984-10-18 1986-11-04 チモ−ジエネテイツクス　インコ−ポレ−テツド 酵母中でプラスミノ−ゲン活性化因子を発現する方法
DE3537176C2 (de) * 1984-10-18 1994-06-09 Zymogenetics Inc Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
CN86107554A (zh) 1987-08-26
SK776486A3 (en) 1998-06-03
IE63822B1 (en) 1995-06-14
FI872801A0 (fi) 1987-06-24
CZ776486A3 (en) 1996-09-11
EP0243465A1 (en) 1987-11-04
DK320287D0 (da) 1987-06-23
CZ284251B6 (cs) 1998-10-14
SK279041B6 (sk) 1998-06-03
HUT43624A (en) 1987-11-30
AU6543286A (en) 1987-05-19
JPS63501614A (ja) 1988-06-23
UA41863C2 (uk) 2001-10-15
WO1987002670A1 (en) 1987-05-07
IE862804L (en) 1987-04-25
JP2523562B2 (ja) 1996-08-14
FI872801A7 (fi) 1987-06-24
AU676132B2 (en) 1997-03-06
HU206897B (en) 1993-01-28
CA1316133C (en) 1993-04-13
DK320287A (da) 1987-06-23
AU7400391A (en) 1991-07-18

Similar Documents

Publication Publication Date Title
CN1027179C (zh) 利用啤酒酵母基因bari分泌异种蛋白的方法
CA1340772C (en) Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
EP0123544A2 (en) Process for expressing heterologous protein in yeast, expression vehicles and yeast organisms therefor
US4588684A (en) a-Factor and its processing signals
CN1032367A (zh) 含有指导异源多肽分泌的克鲁维酵母α-因子前导顺序的DAN组建物
EP3874047B2 (en) Carbon-source regulated protein production in a recombinant host cell
CN1141339A (zh) 用解脂亚罗威阿酵母转化株表达和分泌异源蛋白质
CN88103118A (zh) 人前脱脂蛋白a-i的表达
KR20070009269A (ko) 재조합단백질 생산용 단백질융합인자 라이브러리 및이로부터 획득된 단백질융합인자
EP0220689B1 (en) Method of using bar1 for secreting foreign proteins
US20130273606A1 (en) Secretion yield of a protein of interest by in vivo proteolytic processing of a multimeric precursor
US7198919B1 (en) Use of alpha factor sequences in yeast expression systems
EP3752617A1 (en) Host cell for producing a protein of interest
EP2275556B1 (en) Rapid screening method of translational fusion partners for producing recombinant proteins and translational fusion partners screened therefrom
CN103102418A (zh) 粒细胞集落刺激因子(G-CSF)及其突变体(mG-CSF)与人血清白蛋白第三结构域(3DHSA)的融合蛋白及应用
KR100798894B1 (ko) 재조합단백질 생산용 단백질융합인자
CN1187451C (zh) 在转化的酵母细胞中生产蛋白质的方法
JP3732516B2 (ja) タンパク質の製造法
EP3015548B1 (en) Novel polypeptide, and use thereof
EP4638756A1 (en) Host cells with pat1 knockout for increased specific protein productivity
KR100626753B1 (ko) 재조합 단백질 생산용 맞춤형 단백질융합인자의 초고속선별 방법
CN1302333A (zh) 在酵母中制备目的多肽的方法
CN1029988C (zh) 水蛭素衍生物
EP0188555A1 (en) Yeast cloning vehicle
CN121736923A (zh) 一种在毕赤酵母中表达曲妥珠单抗的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term